

- 17 -

Claims

- 1) A pharmaceutical composition containing N-acetyl-cysteine and Doxorubicin in amounts effective to show a synergistic effect in the inhibition of cancer metastasis formation.
- 2) A kit comprising N-acetyl-cysteine and Doxorubicin in amounts synergistically effective in the inhibition of cancer metastasis formation as well as a medium for the administration thereof.
- 3) A process for the preparation of a pharmaceutical composition containing N-acetyl-cysteine and Doxorubicin for the inhibition of cancer metastasis formation.
- 4) A composition according to claim 1 wherein N-acetyl-cysteine is contained in amounts comprised between 100 mg and 6 g.
- 5) A composition according to claim 1 wherein Doxorubicin is contained in amounts comprised between 1 and 50 mg.
- 6) A kit according to claim 2 wherein N-acetyl-cysteine is contained in amounts comprised between 100 mg and 6 g.
- 7) A kit according to claim 2 wherein Doxorubicin is contained in amounts comprised between 1 and 50 mg.
- 8) A process for the preparation of a pharmaceutical composition according to claim 3 wherein N-acetyl-cysteine is contained in amounts comprised between 100 mg and 6 g.
- 9) A process for the preparation of a pharmaceutical composition according to claim 3 wherein Doxorubicin is contained in amounts comprised between 1 and 50 mg.
- 10) A method for inhibiting cancer metastasis formation in a host comprising the administration to the host of a synergistically effective amount of N-acetyl-cysteine and Doxorubicin.
- 11) A method for inhibiting cancer metastasis formation in a host according to claim 10 wherein N-acetyl-cysteine is administered in an amount between 100 mg and 6 g/day.

- 18 -

12) A method for inhibiting cancer ~~metastasis~~ formation in a host according to claim 10 wherein Doxorubicin is administered in an amount between 1 and 50 mg per dose.

or 100 mg

Add  
B<sub>1</sub> >091502 1448  
054211 22052160